Conivaptan (hydrochloride)
CAY-23728-50 50 mg
Data Sheet: 
SDS:
SDS:
CAS
168626-94-6
Formulation
A solid
Purity
≥95%
MW
535
Shipment
4
Long Term Storage
4
Shelf Life
1460
Description
A vasopressin V1A and V2 receptor antagonist (Kis = 0.48 and 3.04 nM for rat liver V1A and kidney V2, respectively); competitively inhibits oxytocin binding to rat uterine oxytocin receptors (Ki = 44 nM) but has no effect on AVP binding to anterior pituitary V1B receptors at concentrations up to 100 μM in a radioligand binding assay; suppresses AVP-induced increases in intracellular calcium in VSMCs and the pressor response in pithed rats; increases urine output and decreases urine osmolality in dehydrated conscious rats in a dose-dependent manner; reduces brain edema and blood-brain barrier disruption in a mouse experimental stroke model
ESCLUSIVAMENTE PER USO DI RICERCA (RUO) e non per uso terapeutico o diagnostico su uomini o animali. Il prodotto NON è un Dispositivo Medico o un Diagnostico in Vitro.
PRODUCT FOR RESEARCH USE ONLY (RUO) and not for therapeutic or diagnostic use on humans or animals. The product is NOT a Medical Device or an In-Vitro Diagnostic (IVD).
